Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Johnson & Johnson Gets FDA Approval for Imaavy to Treat Warm Autoimmune Hemolytic Anemia

25 August 2026 · By · Wire by Fusion42

Published

25 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at marketwatch.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

Johnson & Johnson received FDA approval for Imaavy (nipocalimab-aahu), the first therapy proven safe and effective to treat warm autoimmune hemolytic anemia in patients aged 12 and older who have used corticosteroids.

This Wire brief sits within Fusion42's coverage of Biotech, and 11 sources have reported it between 24 Aug 2026 and 1 Sep 2026.

◆ ◆ The Wire takeaway

You must reposition your rare disease treatments as FDA approvals open new market access in autoimmune anaemia. The approval cuts your entry barriers in this underserved indication and accelerates potential uptake.

◆ Coverage

11 sources · first reported 24 Aug 2026 · latest 1 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalautoimmune-diseasebiotechrare-diseasejohnson-johnson